Michelle Solly$LLY Here’s the PR
“Based on an updated dataset from the trial reviewed on October 26, no additional COVID-19 patients in this hospitalized setting will receive bamlanivimab...bamlanivimab is unlikely to help hospitalized COVID-19 patients recover”
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
Michelle Solly$CATB Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
PolarisDMD Trial Did Not Achieve Primary or Secondary Endpoints
Vertex today provided an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).
Michelle Solly$VRTX Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
- Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data
Early cancer detection could identify tumors when outcomes are superior at a time
when outcomes are superior and treatment is less morbid. This prospective case-control
sub-study (from NCT02889978 and NCT03085888) assessed the performance of...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered...
Michelle Solly$IONS $AKCA Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash